title: [A cross-sectional case study of human immunodeficiency virus and tuberculosis co-infection in mainland China].
abstract: OBJECTIVE
  In order to take an insight into the profile of HIV/AIDS and tuberculosis (TB) co-infection, we made a statistic survey in 9 hospitals in mainland China. With the purpose of guiding the prevention and treatment, 241 cases with such co-infection were enrolled and the data with respect to clinical manifestations, laboratory tests, therapy and prognosis were analysed.
  
  
  METHODS
  All indices were collected with unified questionary.
  
  
  RESULTS
  Young men (75.9%) took constituted the majority. HIV was transmitted mainly by intravenous drug use (IDU) in Xinjiang and Yunnan provinces, by blood transfusion or blood products in Shanghai, Henan and Wenxi county of Shanxi, and by sexual transmission in Fuzhou, Shanghai, Shenzhen and Dehong prefecture of Yunnan province. In this survey, pulmonary TB accounted for 59.3%, extra-pulmonary TB for 21.2%, and both for 19.5% of the patients. As for laboratory tests, only 9.5% was positive in sputum for acid-fast bacillus (AFB) and 2.9% in culture, 10.8% of the patients had AFB in pleural fluid or cerebrospinal fluid. Besides, PPD was negative or weakly positive in most of the cases. Overall, 76.8% of the 241 cases had a CD(4) cell count < 200/microl, and 58.5% < 100/microl. 80.5% of the patients was treated with anti-tuberculous medications and 69.7% with highly active antiretroviral therapy (HAART). 203 (84.2%) were still alive and 38 (15.8%) died.
  
  
  CONCLUSIONS
  (1) The clinical manifestations of the 241 cases were varied because of prevailing pulmonary TB. (2) The immune function was depressed with reducing CD(4) counts in most of the patients. (3) Positivity rate of examination relevant to TB was too low to help the diagnosis. (4) The mortality (15.8%) was high even with HAART and/or chemotherapy.
authors.affiliation: Shanghai Public Health Center, Fudan University, Shanghai 201508, China. luhongzhou@fudan.edu.cn
authors.forename: Hong-zhou
authors.initials: HZ
authors.lastname: Lu
authors.forename: Yue-xin
authors.initials: YX
authors.lastname: Zhang
authors.forename: Zeng-quan
authors.initials: ZQ
authors.lastname: Zhou
authors.forename: Han-hui
authors.initials: HH
authors.lastname: Ye
authors.forename: Qing-xia
authors.initials: QX
authors.lastname: Zhao
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Fu-xiang
authors.initials: FX
authors.lastname: Wang
authors.forename: Wang-qian
authors.initials: WQ
authors.lastname: Jia
authors.forename: Hong-qing
authors.initials: HQ
authors.lastname: Sun
authors.forename: Xue-yan
authors.initials: XY
authors.lastname: Jiang
authors.forename: Li-min
authors.initials: LM
authors.lastname: Ding
authors.forename: Yan
authors.initials: Y
authors.lastname: Su
authors.forename: Yun
authors.initials: Y
authors.lastname: He
authors.forename: Wubuer
authors.initials: W
authors.lastname: Maimaitiaili
authors.forename: Aibaidoula
authors.initials: A
authors.lastname: Yibaguli
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Sun
authors.forename: Bao-rong
authors.initials: BR
authors.lastname: Liu
authors.forename: Ya-dong
authors.initials: YD
authors.lastname: Hu
authors.forename: Wei
authors.initials: W
authors.lastname: Tang
authors.forename: Bo-ping
authors.initials: BP
authors.lastname: Zhou
authors.forename: Yun-zhen
authors.initials: YZ
authors.lastname: Cao
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology*; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002681:China / Q000453:epidemiology; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology*; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D011379:Prognosis; D014376:Tuberculosis / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000995:Antitubercular Agents